Roche’s Lymphoma Drug With Chemo Extends Survival In Pretreated Patients
Roche study results show prolonged survival in R/R diffuse large B-cell lymphoma patients treated with Columvi (glofitamab) + GemOx vs. Rituxan + GemOx.
Small-Cap Cancer Drug Developer Agenus’ Highlights Encouraging Data From Colorectal Cancer, But Funding Concerns Loom
The latest Phase 1 trial results of Agenus' botensilimab and balstilimab (BOT/BAL) combination therapy for metastatic CRC showcase promising clinical activity.
Penny Stock PaxMedica’s African Sleeping Sickness Candidate Moves Closer To FDA Marketing Application Submission, Stock Rallies
PaxMedica achieves pivotal milestone with completion of three registration/validation batches for PAX-101, an IV suramin formulation, advancing towards FDA submission in Q4 2024. Potential breakthrough treatment for Stage 1 HAT, a fatal tropical disease.
Eli Lilly Suffers Legal Loss For Its Popular Weight Loss/Diabetes Drug In Lawsuit Against Florida Compounding Pharmacy
U.S. District Judge Roy Altman's ruling prohibits Eli Lilly from using state law to halt RXCompoundStore.com's marketing of its tirzepatide version. The court asserts federal law enforcement authority, dismissing Lilly's state law maneuvering.
Animal Health Giant Zoetis Stock Crumbles: Possible Side Effect Of Its Pet Arthritis Pain Drugs Sickened Dogs, Cats
Zoetis' Solensia and Librela, pioneering arthritis treatments for pets. Despite recent concerns, Zoetis defends their safety record, emphasizing positive outcomes for millions of treated animals.
Novo Nordisk/Eli Lilly’s Weight Loss Drugs Does Not Cause Suicidal Behaviors – After FDA, European Medicines Agency Says
The European Medicines Agency's Pharmacovigilance Risk Assessment Committee found no conclusive evidence linking GLP-1 receptor agonists to suicidal or self-injurious thoughts. Following thorough reviews and data analyses, no changes to product information were deemed necessary.
Small-Cap Firm Century Therapeutics’ Expands into Autoimmune Diseases, Analyst Says Clade Therapeutics Acquisition Intriguing
Century Therapeutics unveils plans to expand CNTY-101 clinical development into additional autoimmune diseases, including systemic lupus erythematosus. $60 million private placement supports R&D activities. Acquisition of Clade Therapeutics enhances pipeline with iPSC-focused programs.
Vertex’s Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept’s Potential Impact
Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion, expanding into nephrology with promising APOL1-mediated kidney disease treatments. Analysts foresee significant revenue growth potential, with Alpine's lead molecule poised to add over $5 billion in sales.
Eye Drug Eylea Price Manipulation: Regeneron Faces US Justice Department Allegations Over Medicare Pricing Of Its Best-Selling Eye Drug
The U.S. Justice Department accuses Regeneron Pharmaceuticals of Medicare fraud related to its macular degeneration drug, Eylea. Allegations include manipulating drug prices, resulting in inflated Medicare expenses.
Enliven Therapeutics Shares First Look At Safety, Clinical Activity Of Lead Program
Enliven Therapeutics' Phase 1 trial results for ELVN-001 in chronic myeloid leukemia (CML) patients. Explore the promising safety and efficacy data.